Alzheon Stock
Alzheon is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, with an emphasis on Alzheimer’s disease. Its lead drug candidate, ALZ-801, is an oral treatment designed to target toxic amyloid oligomers, aiming to slow or prevent cognitive decline in patients at risk for Alzheimer’s.
Founded: 2013
For more Alzheon stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Martin Tolar Founder, President, and Chief Executive Officer |
| John Hey Chief Scientific Officer |
| Susan Abushakra Chief Medical Officer |
| Kenneth Mace Chief Financial Officer |
